Endogenex Inc. Welcomes Krissy Wright as New Chief Financial Officer, Aiming for Diabetes Innovation

Endogenex Inc. Welcomes Krissy Wright as Chief Financial Officer

Endogenex, Inc., a clinical-stage medical device company focused on revolutionizing diabetes management, has made a significant move by appointing Krissy Wright as its new Chief Financial Officer (CFO). This strategic leadership change is set to bolster the company's efforts in curating innovative financial strategies and advancing its clinical initiatives, particularly in the development of novel solutions for type 2 diabetes.

Leadership Vision

According to Stacey Pugh, CEO of Endogenex, the addition of Wright to the leadership team is a pivotal moment for the company. Wright brings extensive experience in finance, corporate development, and leadership within the MedTech industry, having previously served as CFO at Cleerly, an AI-driven heart diagnostics company. Her illustrious career includes significant roles at Medtronic where she was VP and General Manager of Brain Modulation, and Vice President & CFO for the Neuromodulation Operating Unit. Before her tenure at Medtronic, Wright honed her expertise over 11 years at PricewaterhouseCoopers, specializing in Audit, Assurance, and Transaction Services.

Wright expressed her enthusiasm for joining Endogenex at such a crucial point in the company’s evolution, emphasizing that the innovative approach of the ReCET procedure could potentially transform diabetes management for millions of individuals worldwide. She is eager to contribute her financial acumen to support this pioneering therapy in the fight against type 2 diabetes.

The ReCET Procedure: A New Horizon for Diabetes Management

At the heart of Endogenex's mission is the ReCET Procedure, a cutting-edge outpatient treatment that targets cellular abnormalities in the duodenum, which are known to contribute to the onset and progression of type 2 diabetes. The procedure operates through controlled, non-thermal pulsed electric fields that stimulate the body’s natural regenerative processes, reinstating proper cellular signaling and enhancing glycemic control.

Currently undergoing global pre-commercialization trials, the ReCET Procedure aims to assess its safety and efficacy among adults struggling with type 2 diabetes, especially those inadequately controlled by existing medications. The FDA has granted the ReCET Procedure Breakthrough Device Designation, highlighting its potential impact on diabetes treatment.

Endogenex, based in Minneapolis, MN, was established in collaboration with Mayo Clinic, reflecting its commitment to improving outcomes for individuals affected by type 2 diabetes. The company is determined to explore therapeutic avenues beyond pharmaceutical interventions in order to rectify metabolic function and help patients regain control over their blood glucose levels.

As Wright steps into her role, both she and Endogenex are poised to make significant strides in the medical landscape, particularly in the management of chronic illnesses like diabetes. With the innovative direction of the company and the expert financial guidance of its new CFO, the future looks promising for transformative solutions in healthcare.

For additional details, visit Endogenex's official website at www.endogenex.com.